MedTrace Logo

8-Chloro-Adenosine in Chronic Lymphocytic Leukemia

NCT00714103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-10-13

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest safe dose of the drug 8-chloro-adenosine that can be given in the treatment of chronic lymphocytic leukemia (CLL). Another goal is to learn how effective the drug is at treating leukemia.

Conditions

Interventions

DRUG

8-Chloro-Adenosine

45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • FDA Office of Orphan Products Development

    collaborator FED

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • William G. Wierda, M.D. · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714103 on ClinicalTrials.gov